Document is current
Any future updates will be listed below
-
Authors
Thomas, Geethu Emily
Egan, Grace
García-Prat, Laura
Botham, Aaron
Voisin, Veronique
Patel, Parasvi S.
Hoff, Fieke W.
Chin, Jordan
Nachmias, Boaz https://orcid.org/0000-0002-7341-2167
Kaufmann, Kerstin B.
Khan, Dilshad H.
Hurren, Rose
Wang, Xiaoming
Gronda, Marcela
MacLean, Neil
O’Brien, Cristiana
Singh, Rashim P.
Jones, Courtney L.
Harding, Shane M. https://orcid.org/0000-0002-5524-3566
Raught, Brian
Arruda, Andrea
Minden, Mark D.
Bader, Gary D. https://orcid.org/0000-0003-0185-8861
Hakem, Razq
Kornblau, Steve
Dick, John E.
Schimmer, Aaron D. https://orcid.org/0000-0003-4023-3899
- License Information
-
More Information
Article History
Received: 11 May 2021
Accepted: 22 April 2022
First Online: 6 June 2022
Competing interests
: A.D.S. has received research funding from Takeda Pharmaceuticals and Medivir AB as well as consulting fees/honorarium from Takeda, Novartis, Jazz and Otsuka Pharmaceuticals. A.D.S. is named on a patent application for the use of DNT cells to treat AML (US patent application no. US62/971,534). The remaining authors declare no competing interests.
